Research Article
Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
Table 4
Markov model input parameters for chronic pouchitis.
| Health states | Transition probabilities (%)/cycle | Costs (CA$)/cycle | Utility scores/year |
| (M) Response to ADA 1 | | 4,442 (±25%) | 0.58 (±0.15) | (1) Response to ADA 1 | See Table 5 | | | (2) Lost response (unwell 1) | # | | | (3) ADA complication 1 | 4.20 | | |
| (N) Unwell 1 | | 917 (±25%) | 0.32 (±0.31) | (1) Unwell 1 | # | | | (2) Surgery 1 | 10.00 | | | (3) Steroid complication 1 | 2.80 | | |
| (O1) ADA complication 1 in the ADA not available arm | | 12,059 (±25%) | 0.16 (±0.16) | (1) Response to ADA 1 | 60.00 | | | (2) Unwell 1 | 19.00 | | | (3) Surgery 1 | 19.00 | | | (4) Death | # | | |
| (O2) ADA complication 1 in the ADA available arm | | 12,059 (±25%) | 0.16 (±0.16) | (1) Response to ADA 1 | 51.00 | | | (2) Unwell 1 | 23.50 | | | (3) Surgery 1 | 23.50 | | | (4) Death | # | | |
| (P) Surgery 1 (permanent ileostomy) | | 37,159 (±25%) | 0.16 (±0.16) | (1) Response 1 | # | | | (2) Surgery complication 1 | 12.80 | | | (3) Death | 2.50 | | |
| (Q) Steroid complication 1 | | 23,919 (±25%) | 0.16 (±0.16) | (1) Surgery 1 | 98.00 | | | (2) Death | # | | |
| (R) Response to surgery 1 | | 0 | 0.44 (±0.11) | (1) Response to surgery 1 | # | | | (2) Surgical complication 1 | 2.50 | | |
| (S) Surgical complication 1 | | 17,586 (±25%) | 0.37 (±0.24) | (1) Response to surgery | # | | | (2) Death | 0.50 | | |
|
|
#: complement probability.
|